Kidney disease-focused drug developer Walden was co-founded by faculty members of Rush University and Harvard University earlier this year.
US-based kidney disease treatment developer Walden Biosciences launched on Tuesday with $51m it secured in a series A round to advance research conducted by faculty at Rush and Harvard universities.
The round was co-led by pharmaceutical company UCB’s corporate venturing fund, UCB Ventures, and venture capital firm Arch Venture Partners.
Founded earlier this year, Walden is working on therapeutics designed to restore renal function in the body by targeting cells specific to the kidney and its biologic processes, and in doing so reverse the progress of kidney disease.
The startup’s co-founders include Jochen Reiser, chairman of Rush University Medical Center’s Department of Internal Medicine, Ralph Brown, professor of medicine at the same university’s Rush Medical College, and Sanja Sever, associate professor of medicine at Harvard Medical School.
Ari Nowacek, a principal at Arch Venture Partners, is also co-founder of Walden. Emmanuel Lacroix, vice-president and partner at…
